Conclusively, our findings indicate that oncogenic lncRNA MALAT1 protects prostate cancer tumor cells from anticancer agents by initiating the HR pathway, revealing a potential therapeutic vulnerability that can be exploited by targeting MALAT1 or overexpressing miR-421 in conjunction with PARPi. The gene discussed is MALAT1; the disease is prostate carcinoma.